AxeroVision is developing novel therapies for the treatment of ophthalmic inflammatory diseases, such as Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). AXR-159 is being developed for the treatment of chronic DED. AXR-270 is being developed for the short-term treatment of DED. Both assets have achieved clinical proof-of-concept.